ClinicalTrials.gg
WithdrawnNCT02893995Updated May 9, 2017

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

A Phase 4 interventional study of Slow Dose Titration Group of Subcutaneous Treprostinil and Rapid Dose Titration Group of Subcutaneous Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Withdrawn at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
38th of 44
0 · median 32
Started
2017
with 3 others
Phase 4
14 of 44
1 open now
Registered
27th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 38th largest by enrollment, is one of 4 that started in 2017, is one of 14 in phase 4, and was the 27th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose titration regimens of subcutaneous Remodulin infusion in subjects with pulmonary arterial hypertension (PAH). The study will include about 50 subjects at up to 10 clinical trial centers in China. The treatment phase of the study will last approximately 16 weeks. Subjects who complete all required assessments will also be eligible to enter a long-term open-label, extension study (CVT-CV-004).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • Subcutaneous Treprostinil
  • Remodulin
  • 6 Minute Walk Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject is eligible for inclusion in this study if all of the following criteria apply:

  1. The subject voluntarily gives written to participate in the study.
  2. The subject is at least 18 years of age at screening.
  3. The subject weighs a minimum of 40 kg with a less than 40 kg/m2 at screening.
  4. The subject has a diagnosis of idiopathic or heritable PAH, PAH associated with repaired congenital systemic-to-pulmonary shunts (at least one year since repair with respect to the date of providing informed consent), or PAH associated with connective tissue diseases.
  5. The subject must have a baseline 6MWD between 150 and 550 meters, inclusive, in the absence of a concurrent injury, illness (other than PAH or a PAH related condition), or other confounding factor that would prevent the accurate assessment of the subject's exercise capacity.
  6. The subject is either treatment naïve or is receiving a PDE-5 inhibitor and/or an ERA for at least 60 days prior to screening and on a stable dose for at least 30 days prior to screening and is willing to remain on a PDE-5 inhibitor and/or an ERA at the same dose for the duration of the 16-week treatment phase.
  7. The subject must be optimally treated with conventional pulmonary hypertension therapy (e.g., oral vasodilators, oxygen, digoxin, etc.) with no additions, discontinuations, or dose changes for at least 14 days prior to screening (excluding diuretics and anticoagulant dose adjustments).
  8. The subject has undergone right heart catheterization during the screening period (or within 3 years before screening) and been documented to have a mean pulmonary artery pressure (PAPm) of greater than or equal to 25 mmHg, a pulmonary arterial wedge pressure (PAWP) of less than or equal to 15 mmHg, and pulmonary vascular resistance (PVR) of more than 3 Wood units.
  9. The subject has undergone echocardiography within 7 days prior to randomisation with evidence of clinically normal left systolic and diastolic ventricular function, absence of any left sided heart disease (e.g., mitral valve stenosis) and absence of unrepaired congenital heart disease. Subjects with clinically insignificant left ventricular diastolic dysfunction due to the effects of right ventricular overload (i.e., right ventricular hypertrophy and/or dilatation) will not be excluded.
  10. The subject has a previous ventilation perfusion lung scan and/or high resolution computerized tomography scan of the chest and/or pulmonary angiography that are consistent with the diagnosis of PAH (e.g., low probability of pulmonary embolism; absence of major perfusion defects).
  11. The subject has pulmonary function tests done within 9 months prior to or during the screening period with the following:

    1. Total lung capacity (TLC) is at least 60% (of predicted value)
    2. /forced vital capacity (FEV1/FVC) ratio is at least 50%
  12. Sexually active women of must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use two different forms of highly effective . Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptive (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device (IUD), or (4) partner vasectomy. For women of childbearing potential, a negative serum pregnancy test is required at screening and a negative hCG urine pregnancy test is required at baseline visit. Women of child bearing potential include any females who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are not (defined as amenorrhea for at least 12 consecutive months).

    Males participating in the study must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.

  13. In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits, and is mentally and physically capable of learning to administer Remodulin by continuous SC infusion using a micro infusion pump.

Exclusion criteria

Exclusion Criteria:

A subject is not eligible for inclusion in this study if any of the following criteria apply:

  1. The subject is pregnant or lactating.
  2. The subject has received epoprostenol, treprostinil, iloprost or beraprost within 90 days prior to screening (except if used during acute vasoreactivity testing).
  3. The subject has had previous intolerance or lack of efficacy to prostacyclin or a prostacyclin analogue that resulted in discontinuation or inability to titrate that therapy effectively.
  4. The subject has any disease associated with PH other than idiopathic or heritable PAH, or PAH associated with repaired (for at least one year) congenital systemic-to-pulmonary shunts or connective tissue diseases or has had an atrial septostomy.
  5. The subject is in WHO functional class IV.
  6. The subject has a current diagnosis of uncontrolled sleep apnea as defined by their physician.
  7. The subject has liver function tests ( or ALT) greater than three times the upper limit of the laboratory reference range.
  8. The subject has a history of active gastro-intestinal ulcer, intracranial hemorrhage, injury or other cause of bleeding episode within 6 months before screening, or any other disease / condition that would either jeopardize the safety of the subject and / or interfere with the interpretation of study assessments in the opinion of the Investigator.
  9. The subject has a history of ischemic heart disease including previous myocardial infarction or symptomatic coronary artery disease within 6 months before screening, or history of left sided myocardial disease as evidenced by a PAWP (or left ventricular end-diastolic pressure) greater than 15 mmHg or (LVEF) less than 40%.
  10. The subject has uncontrolled systemic hypertension as evidenced by systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.
  11. The subject has systemic hypotension as evidenced by systolic blood pressure less than 85 mmHg
  12. The subject has a musculoskeletal disorder (e.g., arthritis affecting the lower limbs, recent hip or knee joint replacement, artificial leg) or any other disease that is likely to limit ambulation, or is connected to a machine that is not portable.
  13. The subject has an unstable psychiatric condition or is mentally incapable of understanding the objectives, nature, or consequences of the trial, or has any condition which in the Investigator's opinion would constitute an unacceptable risk to the subject's safety.
  14. The subject is receiving an drug, has an investigational device in place or has participated in an investigational drug or device study within 30 days prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Slow Dose Titration Group of Subcutaneous Treprostinil

    Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.

    Drug: Slow Dose Titration Group of Subcutaneous Treprostinil

  • Experimental
    Rapid Dose Titration Group of Subcutaneous Treprostinil

    Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.

    Drug: Rapid Dose Titration Group of Subcutaneous Treprostinil

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Among Subjects through 16 Weeks

    The incidence of adverse events among subjects throughout the 16 week study will be measured by the number of subjects analyzed and the percentage of those subjects who experienced an adverse event.

    Time frame: 16 Weeks

  2. Change in Patient Reported Site Pain from Baseline to Week 16

    The site pain questionnaire is a 10-point scale rating the worst site pain experienced on a measured day. Scores will range from 0 (no pain) to 10 (worst possible pain). The questionnaire will be completed each time a new infusion site is placed and until a subject's infusion site pain level reaches a score of zero for two consecutive days or they have completed 14 days. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  3. Incidence of Subject Discontinuations Among Participants through 16 Weeks

    The incidence of subject discontinuations among subjects throughout the 16 week study will be measured by the number of subjects analyzed and the percentage of those participants who discontinued.

    Time frame: 16 Weeks

Secondary outcomes

  1. Change in 6-minute Walk Distance (6MWD) from Baseline to Week 16

    The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). Subjects will be instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  2. Change in Borg Dyspnea Score (following 6MWT) from Baseline to Week 16

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score will be assessed immediately following the 6MWT. Scores range from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced). Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  3. Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations from Baseline to Week 16

    The N-terminal pro-BNP (NT-proBNP) serum concentration will be assessed as a biomarker to compare the severity of heart failure at Baseline and Week 16. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  4. Number of Participants with a Change from Baseline World Health Organization (WHO) Functional Classification at Week 16

    The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Change from Baseline at Week 16

  5. Change in PAH Symptoms from Baseline to Week 16

    Symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea will be assessed and if present, the intensity of the symptom will be rated as mild, moderate, or severe. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Change from Baseline at 16 Weeks

  6. Change in Measured Tricuspid Annular Plane Systolic Excursion (TAPSE) from Baseline to Week 16

    Change in right ventricular function will be assessed using the tricuspid annular plane systolic excursion (TAPSE) as determined by echocardiography. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  7. Change in Measured Tricuspid Regurgitant Jet Velocity (TRJV) from Baseline to Week 16

    Change in right ventricular function will be assessed using the tricuspid regurgitant jet velocity (TRJV) as determined by echocardiography. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  8. Incidence of Pericardial Effusion from Baseline to Week 16

    Change in right ventricular function will be assessed by the presence or absence of pericardial effusion as determined by echocardiography. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed.

    Time frame: Baseline and Week 16

  9. Measure treprostinil plasma concentration from Week 4 to Week 16

    During the treatment phase at Weeks 4, 8, 12, and 16 or at the time of premature study termination, a single blood sample will be collected to measure treprostinil plasma concentration.

    Time frame: Week 4, Week 8, Week 12, and Week 16

07

Study locations

10 sites
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, 100029, China
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Fu Wai Hospital
    Beijing, 100037, China
  • Beijing Shijitan Hospital
    Beijing, 100038, China
  • Xiangya Hospital Centre South University
    Changsha, 410008, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Zhongshan Hospital affiliated with Fudan University
    Shanghai, 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • Wuhan Asia Heart Hospital
    Wuhan, 430022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2017; primary completion for Apr 2018, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2016
First posted
Sep 9, 2016
StartEst.
Feb 2017
Primary completionEst.
Apr 2018
CompletionEst.
Apr 2018
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02893995
Collaborators
CVie Therapeutics Co. Ltd.
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Feb 2017 (estimated)
Primary completion
Apr 2018 (estimated)
Completion
Apr 2018 (estimated)
Last update
May 9, 2017

Study contacts

Junbo Ge
principal investigator · Zhongshan Hospital affiliated with Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion